Laparoscopic Versus Open Partial Nephrectomy - Surgical and Oncological Outcomes (LapVsOpen prtn)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Shay Golan, MD
- Phone Number: 972-50-7447573
- Email: shaygo1@yahoo.com
Study Locations
-
-
-
Petach Tikva, Israel
- Recruiting
- Rabin Medical Center
-
Contact:
- shay golan, MD
- Phone Number: 972-50-3447573
- Email: shaygo1@yahoo.com
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- patients referred to partial nephrectomy
Exclusion Criteria:
- Contra-indication for laparocopic surgery
- Complexed , large tumors, single kidney, chronic renal failure
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Laparoscopic partial nephrectomy
|
Laparoscopic partial nephrectomy
|
|
Open Partial nephrectomy
|
Open partial nephrectomy
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion
Primary Completion
Study Completion
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- 5489
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Tumor
-
NCT06911333RecruitingSolid Tumor | Solid Tumor Cancer | Solid Tumor, Adult | Solid Tumor, Unspecified, Adult | Tumor, Solid | Solid Tumor in Advanced Stage | Solid Tumors Refractory to Standard Therapy
-
NCT04809012WithdrawnSolid Tumor | Relapsed Solid Tumor | Refractory Tumor
-
NCT04942717RecruitingSolid Tumor | Solid Tumor, Adult | Solid Tumor, Unspecified, Adult
-
NCT04537936RecruitingSolid Tumor | Solid Tumor, Adult | Solid Tumor, Unspecified, Adult
-
NCT04015609RecruitingSolid Tumor | Solid Tumor, Adult | Solid Tumor, Unspecified, Adult
-
NCT05661461RecruitingAdvanced Solid Tumor | Tumor | Tumor, Solid
-
NCT04914117CompletedMetastatic Solid Tumor | Locally Advanced Solid Tumor | Unresectable Solid Tumor
-
NCT03491345Active, not recruitingPD-L1 Positive Mutation Tumor | EBV Positive Mutation Tumor | MSI-H Mutation Tumor | POLE/POLD1 Mutation Tumor
-
NCT07225088RecruitingSolid Tumor | Solid Tumor, Adult
Clinical Trials on Laparoscopic partial nephrectomy
-
NCT06424080Recruiting
-
NCT06969131CompletedPartial Nephrectomy | Laparoscopic | Renal Tumors | Pentafecta
-
NCT04933604CompletedKidney Neoplasms | Urologic Neoplasms | Renal Cell Carcinoma | Surgery | Kidney Injury | Renal Cancer | Oncology | Urologic Cancer | Renal Neoplasm | Kidney Ischemia
-
NCT06960135CompletedTrifecta Achievement | Pentafecta Achievement
-
NCT05486871Not yet recruiting
-
NCT06532422Recruiting
-
NCT02849119UnknownRenal Cell Carcinoma
-
NCT02326558Completed
-
NCT03259477Unknown